Due to our interest in the impact of age and immunosenescence on cancer immunity, we elected to study newly-diagnosed older women and found that the ability of patient's PBMCs to respond to TAA in vitro, in this case to her2/neu peptides, was also informative for breast cancer (32). The gene discussed is ERBB2; the disease is cancer.